Powder: -20°C for 3 years | In solvent: -80°C for 1 year
UNC2025 (mrx-6313)(IC50 of 0.74 nM and 0.8 nM) is a potent and orally bioavailable dual MER/FLT3 inhibitor. UNC-2025 is about 20-fold selectivity higher than Axl and Tyro3.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
2 mg | 在庫あり | ¥ 7,500 | |||
5 mg | 在庫あり | ¥ 12,000 | |||
10 mg | 在庫あり | ¥ 19,500 | |||
25 mg | 在庫あり | ¥ 29,000 | |||
50 mg | 在庫あり | ¥ 47,500 | |||
100 mg | 在庫あり | ¥ 85,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 12,500 |
説明 | UNC2025 (mrx-6313)(IC50 of 0.74 nM and 0.8 nM) is a potent and orally bioavailable dual MER/FLT3 inhibitor. UNC-2025 is about 20-fold selectivity higher than Axl and Tyro3. |
ターゲット&IC50 | FLT3:0.8 nM, Mer:0.74 nM |
In vitro | In 697 B-ALL cells, UNC-2025 potently inhibits Mer phosphorylation with IC50 of 2.7 nM. In A549 NSCLC and Molm-14 AML cell lines, UNC-2025 causes significant inhibition of colony formation dependent on Mer8 and Flt3. [1] In H2228 and H1299 cell lines, UNC-2025 inhibits MERTK oncogenic signaling downstream, such as basal and stimulated pAKT and pERK1/2. In four NSCLC cell lines, UNC-2025 also induces apoptotic cell death, and decreases colony formation. [2] |
In vivo | In mice bearing 697 acute leukemia tumors, UNC-2025 (3 mg/kg, p.o.) shows good solubility and DMPK properties, and results in effective target inhibition. [1] In mice bearing H2228 or A549 tumors, UNC-2025 (50 mg/kg, p.o.) inhibits tumor growth. [2] |
別名 | mrx-6313, UNC-2025, UNC 2025 |
分子量 | 476.66 |
分子式 | C28H40N6O |
CAS No. | 1429881-91-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: Insoluble
Ethanol: 8 mg/mL(15.59 mM), Heating is recommended.
DMSO: 25 mg/mL(48.72 mM), Heating is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
UNC2025 1429881-91-3 Angiogenesis Tyrosine Kinase/Adaptors FLT TAM Receptor Inhibitor inhibit FLT3 leukemia CD135 Fms like tyrosine kinase 3 acute mrx-6313 Cluster of differentiation antigen 135 cancer MERTK UNC-2025 UNC 2025 inhibitor